Payment overview · 2025
General Payments
$520.60
18 reported records · 7 companies
Healthcare provider profile · identity verified
Joseph M Jackson, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBANY, GA · NPI 1811980352
Verified facts
What the public records show
CMS Open Payments records show Joseph M Jackson, MD received $520.60 in general payments during 2025 across 18 reported records.
Astellas Pharma US Inc accounted for 52.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $273.09 | 52.5% | 9 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $110.89 | 21.3% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $37.15 | 7.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $36.60 | 7.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.86 | 6.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.86 | 3.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.15 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.60 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $273.09 | 9 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $110.89 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 649 | 203 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 528 | 171 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 493 | 114 |
| Lisinopril | Lisinopril | 412 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 103 |
| Losartan Potassium | Losartan Potassium | 357 | 111 |
| Metformin Hcl | Metformin Hcl | 329 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 81 |
| Tramadol Hcl | Tramadol Hcl | 265 | 71 |
| Simvastatin | Simvastatin | 250 | 73 |
| Gabapentin | Gabapentin | 231 | 86 |
| Alprazolam | Alprazolam | 225 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 216 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 197 | 37 |
| Omeprazole | Omeprazole | 195 | 74 |
| Lorazepam | Lorazepam | 173 | 36 |
| Potassium Chloride | Potassium Chloride | 171 | 54 |
| Furosemide | Furosemide | 161 | 61 |
| Jardiance | Empagliflozin | 159 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 156 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 49 |
| Trazodone Hcl | Trazodone Hcl | 140 | 58 |
| Montelukast Sodium | Montelukast Sodium | 139 | 50 |
| Famotidine | Famotidine | 138 | 51 |
| Eliquis | Apixaban | 137 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 46 |
| Allopurinol | Allopurinol | 130 | 40 |
| Ozempic | Semaglutide | 125 | 22 |
| Glipizide | Glipizide | 120 | 40 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 118 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 47 |
| Clonazepam | Clonazepam | 114 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 94 |
| Sertraline Hcl | Sertraline Hcl | 103 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 101 | 79 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 29 |
| Glimepiride | Glimepiride | 96 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 15 |
| Celecoxib | Celecoxib | 91 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 29 |
| Carvedilol | Carvedilol | 90 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 30 |
| Meloxicam | Meloxicam | 89 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 24 |
| Pregabalin | Pregabalin | 88 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 23 |
| Atenolol | Atenolol | 85 | 29 |
| Metformin Hcl Er | Metformin Hcl | 85 | 27 |
| Prednisone | Prednisone | 83 | 77 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 31 |
| Mounjaro | Tirzepatide | 79 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 20 |
| Ondansetron Odt | Ondansetron | 69 | 19 |
| Donepezil Hcl | Donepezil Hcl | 68 | 22 |
| Nifedipine Er | Nifedipine | 68 | 18 |
| Farxiga | Dapagliflozin Propanediol | 67 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 67 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Azithromycin | Azithromycin | 64 | 55 |
| Chlorthalidone | Chlorthalidone | 64 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 52 |
| Bupropion Xl | Bupropion Hcl | 58 | 16 |
| Fenofibrate | Fenofibrate | 57 | 15 |
| Temazepam | Temazepam | 54 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 13 |
| Spironolactone | Spironolactone | 52 | 18 |
| Alendronate Sodium | Alendronate Sodium | 49 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 37 |
| Methylprednisolone | Methylprednisolone | 49 | 47 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 11 |
| Valacyclovir | Valacyclovir Hcl | 44 | 21 |
| Myrbetriq | Mirabegron | 43 | 12 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Fluconazole | Fluconazole | 39 | 26 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 17 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 18 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Linzess | Linaclotide | 24 | 11 |
| Mupirocin | Mupirocin | 24 | 17 |
| Telmisartan | Telmisartan | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 14 |
| Torsemide | Torsemide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | 13 |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Finasteride | Finasteride | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.60 · 18 records | Astellas Pharma US Inc | CAPLYTA, CYGNUS DUAL, Korlym, NURTEC ODT, Tymlos, Veozah, ZAVZPRET, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error